-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
“Roll Up Our Sleeves and Work Hard—Press On Undeterred by Wind and Rain” New Data, New Insights | Hebei: Strategic Emerging Industries Achieve Rapid Growth in the First Three Quarters
Category:
发布时间：2023-10-30
【概要描述】
Our province has leveraged policy guidance to stimulate the intrinsic innovation drive of enterprises, foster a favorable innovation ecosystem, and accelerate the development of a more innovative and competitive industrial chain system. In the first three quarters of this year, the value added of strategic emerging industries among large-scale industrial enterprises across the province increased by 6.6% year on year.
Reported by the Jishi Client
Our province is leveraging policy guidance to stimulate enterprises’ intrinsic innovation drive, foster a conducive innovation ecosystem, and accelerate the development of a more innovative and competitive industrial chain system. In the first three quarters of this year, the value added of strategic emerging industries among large-scale industrial enterprises across the province increased by 6.6% year on year.
In recent days, three innovative drugs developed by the team led by Dr. Yang Xian at Shijiazhuang Sihua Pharmaceutical have reached new milestones. The fastest-progressing anti-cancer candidate is nearing completion of Phase I clinical trials; a Class 1 new drug for pulmonary arterial hypertension has already been submitted for clinical approval; and a Class 1 new drug for the treatment of liver fibrosis is about to conclude preclinical studies.
Yang Xian, Head of the Innovation Department at the R&D Center of Shijiazhuang Sihua Pharmaceutical Group:
Our innovative drug R&D pipeline currently covers the areas of oncology, liver diseases, and pulmonary diseases. Throughout the entire drug development process—from drug design and synthesis to formulation, analytical testing, and clinical trials—we are fully capable of conducting all these stages in-house.
Led by Yang Xian’s team, Shijiazhuang Sihua Pharmaceutical is stepping up its research and development efforts on innovative drugs, rare-disease treatments, and medications facing supply shortages, with nearly 200 projects currently in the pipeline. Although early-stage R&D for innovative drugs is time-consuming and capital-intensive, the company’s sustained investment is underpinned by tangible policy incentives, such as the additional deduction of R&D expenses.
Xia Guolong, Deputy General Manager of the R&D Center of Shijiazhuang Sihua Pharmaceutical Group:
Since October of this year, we have applied for and benefited from the policy of additional tax deductions for R&D expenses in the first three quarters, resulting in income tax reductions and exemptions totaling more than RMB 23 million. Coupled with a series of other tax incentive policies, we are expected to receive over RMB 100 million in tax benefits in 2023.
Driven by supportive policies, biopharmaceutical companies—including Shijiazhuang No. 4 Pharmaceutical—have seen consecutive years of increased R&D investment. At the same time, our province is accelerating the establishment of key laboratories at or above the provincial level and promoting collaborative technological breakthroughs through mechanisms such as the “challenge-based recruitment” approach, thereby continuously enhancing the competitiveness of the biopharmaceutical industry. By the end of this year, the biopharmaceutical industry cluster is expected to be the first to surpass RMB 100 billion in operating revenue.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091